Adverse Drug Reaction Reporting Systems

"Adverse Drug Reaction Reporting Systems" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.

Descriptor ID	D016907
MeSH Number(s)	E05.337.800.120 N02.421.668.320.120
Concept/Terms	Adverse Drug Reaction Reporting Systems Adverse Drug Reaction Reporting Systems Drug Reaction Reporting Systems, Adverse

Below are MeSH descriptors whose meaning is more general than "Adverse Drug Reaction Reporting Systems".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Evaluation Studies as Topic [E05.337]
Product Surveillance, Postmarketing [E05.337.800]
Adverse Drug Reaction Reporting Systems [E05.337.800.120]
Health Care [N]
Health Care Facilities, Manpower, and Services [N02]
Health Services [N02.421]
Pharmaceutical Services [N02.421.668]
Drug Information Services [N02.421.668.320]
Adverse Drug Reaction Reporting Systems [N02.421.668.320.120]

Below are MeSH descriptors whose meaning is related to "Adverse Drug Reaction Reporting Systems".

Below are MeSH descriptors whose meaning is more specific than "Adverse Drug Reaction Reporting Systems".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Adverse Drug Reaction Reporting Systems" by people in this website by year, and whether "Adverse Drug Reaction Reporting Systems" was a major or minor topic of these publications.

Bar chart showing 35 publications over 17 distinct years, with a maximum of 4 publications in 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	2	2
2004	1	0	1
2005	0	1	1
2006	2	1	3
2007	1	3	4
2008	3	0	3
2009	0	2	2
2010	1	1	2
2011	2	1	3
2012	1	1	2
2014	1	0	1
2016	0	1	1
2017	2	1	3
2018	0	1	1
2019	2	0	2
2021	2	0	2
2024	1	1	2

Below are the most recent publications written about "Adverse Drug Reaction Reporting Systems" by people in Profiles.

Yukselen Z, Raju AKV, Kumar PA, Ujjawal A, Dasari M, Parajuli S, Nakhla M, Bansal K, Ganatra S, Dani SS. A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten. Am J Cardiovasc Drugs. 2024 Nov; 24(6):791-799.

View in: PubMed
Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024 Sep; 49(9):102664.

View in: PubMed
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).

View in: PubMed
Rawat BPS, Jagannatha A, Liu F, Yu H. Inferring ADR causality by predicting the Naranjo Score from Clinical Notes. AMIA Annu Symp Proc. 2020; 2020:1041-1049.

View in: PubMed
Honvo G, Bannuru RR, Bruy?re O, Rannou F, Herrero-Beaumont G, Uebelhart D, Cooper C, Arden N, Conaghan PG, Reginster JY, Thomas T, McAlindon T. Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Drugs Aging. 2019 04; 36(Suppl 1):145-159.

View in: PubMed
Liu F, Jagannatha A, Yu H. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records. Drug Saf. 2019 01; 42(1):95-97.

View in: PubMed
Fantasia HC, Vooys KM. Public Health Implications of Counterfeit Medications. Nurs Womens Health. 2018 Jun; 22(3):264-268.

View in: PubMed
Bird ST, Gelperin K, Taylor L, Sahin L, Hammad H, Andrade SE, Mohamoud MA, Toh S, Hampp C. Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer's Capture of Spontaneous Reports for Exposed Pregnancies. Drug Saf. 2018 01; 41(1):87-94.

View in: PubMed
Easter SR, Eckert LO, Boghossian N, Spencer R, Oteng-Ntim E, Ioannou C, Patwardhan M, Harrison MS, Khalil A, Gravett M, Goldenberg R, McKelvey A, Gupta M, Pool V, Robson SC, Joshi J, Kochhar S, McElrath T. Fetal growth restriction: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2017 12 04; 35(48 Pt A):6546-6554.

View in: PubMed
Iyer G, Marimuthu SP, Segal JB, Singh S. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System. Drug Saf. 2017 09; 40(9):799-808.

View in: PubMed

People

Explore

Similar Concepts

Top Journals